Celldex Therapeutics, Inc.
CLDXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Celldex Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 29, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Celldex Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-11-13 · Wright Richard M.: Larger than 38 of the 40 other insider sales of Common Stock on file. SEC filing
- 2024-06-07 · Young Diane C.: Larger than 37 of the 40 other insider sales of Common Stock on file. SEC filing
- 2024-06-03 · Heath-Chiozzi Margo: Larger than 39 of the 40 other insider sales of Common Stock on file. SEC filing
- 2024-05-30 · Heath-Chiozzi Margo: Larger than 36 of the 40 other insider sales of Common Stock on file. SEC filing
- 2022-08-15 · Marucci Anthony S: Larger than all 40 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-04 | Jimenez Freddy A. · SVP & GENERAL COUNSEL | Common Stock | S — Open market or private sale | −4,166 | 29.10 | SEC filing |
| 2025-11-13 | Wright Richard M. · Other | Common Stock | S — Open market or private sale | −49,298 | 24.00 | SEC filing |
| 2025-08-13 | Jimenez Freddy A. · SVP & GENERAL COUNSEL | Common Stock | S — Open market or private sale | −341 | 23.95 | SEC filing |
| 2025-08-13 | Jimenez Freddy A. · SVP & GENERAL COUNSEL | Common Stock | S — Open market or private sale | −430 | 25.42 | SEC filing |
| 2024-11-11 | Marucci Anthony S · PRESIDENT & CEO | Common Stock | P — Open market or private purchase | +11,500 | 26.82 | SEC filing |
| 2024-06-14 | Crowley Elizabeth · SR. VP & CPDO | Common Stock | S — Open market or private sale | −30,000 | 34.87 | SEC filing |
| 2024-06-14 | Martin Samuel Bates · SVP AND CFO | Common Stock | S — Open market or private sale | −17,172 | 35.42 | SEC filing |
| 2024-06-07 | Crowley Elizabeth · SR. VP & CPDO | Common Stock | S — Open market or private sale | −15,000 | 35.06 | SEC filing |
Showing 8 of 12 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-25 | Cohen Cheryl · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +26,000 | SEC filing |
| 2026-06-25 | Torres Denice · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +26,000 | SEC filing |
| 2026-06-25 | Brownlie Keith L · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +26,000 | SEC filing |
| 2026-06-25 | Heath-Chiozzi Margo · SVP OF REGULATORY AFFAIRS | Incentive Stock Option (right to buy) | A — Grant, award, or other acquisition | +95,000 | SEC filing |
| 2026-06-25 | PENNER HARRY JR · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +26,000 | SEC filing |
| 2026-06-25 | NEIL GARRY ARTHUR · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +26,000 | SEC filing |
| 2026-06-25 | Marucci Anthony S · PRESIDENT & CEO | Incentive Stock Option (right to buy) | A — Grant, award, or other acquisition | +375,000 | SEC filing |
| 2026-06-25 | CONRAD HERBERT J · Director | Non-Qualified Stock Option (right to buy) | A — Grant, award, or other acquisition | +26,000 | SEC filing |
Showing 8 of 21 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.